FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marja-Liisa Dahl

Research Profile

Chemicals & Drugs

Physiology

Procedures

Living Beings

European Continental Ancestry Group

Concepts & Ideas

Gene Frequency

Co-author Network

Publications

TOP 3
Erik Eliasson; Jonatan D Lindh; Rickard E Malmström; Olof Beck; Marja-Liisa Dahl
Therapeutic drug monitoring for tomorrow.
Sara Margolin; Linda Thorén; Hanjing Xie; Marja-Liisa Dahl; Larissa Koukel; Jonatan D Lindh; Erik Eliasson
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
Klas R Linderholm; Sara K Olsson; Martin Samuelsson; Elisabeth Skogh; Marja-Liisa Dahl; Göran Engberg; Maria Holtze; Sophie Erhardt
Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marja-Liisa Dahl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Erik Eliasson; Jonatan D Lindh; Rickard E Malmström; Olof Beck; Marja-Liisa Dahl
Therapeutic drug monitoring for tomorrow.
European journal of clinical pharmacology 2013;69 Suppl 1():25-32.
2013: Sara Margolin; Linda Thorén; Hanjing Xie; Marja-Liisa Dahl; Larissa Koukel; Jonatan D Lindh; Erik Eliasson
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
Pharmacogenomics 2013;14(6):613-22.
2012: Klas R Linderholm; Sara K Olsson; Martin Samuelsson; Elisabeth Skogh; Marja-Liisa Dahl; Göran Engberg; Maria Holtze; Sophie Erhardt
Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.
Schizophrenia bulletin 2012;38(3):426-32.
2012: Mao Mao; Maria Gabriella Scordo; Elisabeth Skogh; Marja-Liisa Dahl
Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
Journal of clinical psychopharmacology 2012;32(2):287-9.
2011: Osman Gökalp; Arzu Gunes; Maria Gabriella Scordo; Mehmet Numan Tamer; Osman Aydın; Hakan Cam; Erkan Cure; Marja-Liisa Dahl
Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.
European journal of clinical pharmacology 2011;67(12):1223-9.
2011: Elisabeth Skogh; Ingemar Sjödin; Martin Josefsson; Marja-Liisa Dahl
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
Journal of clinical psychopharmacology 2011;31(1):4-9.
2011: Laura Magliulo; Marja-Liisa Dahl; Grazia Lombardi; Silvia Fallarini; Laura Maria Villa; Aldo Biolcati; Maria Gabriella Scordo
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
European journal of clinical pharmacology 2011;67(1):47-54.
2010: Kristina Melkersson; Arzu Gunes; Marja-Liisa Dahl
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients.
Human psychopharmacology 2010;25(4):347-52.
2010: A-K Hamberg; Mia Wadelius; Jonatan D Lindh; Marja-Liisa Dahl; Roberto Padrini; Panos Deloukas; Anders Rane; E Niclas Jonsson
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.
Clinical pharmacology and therapeutics 2010;87(6):727-34.
2010: Karin Hedenmalm; Gunnar Alvan; Patrik Ohagen; Marja-Liisa Dahl
Muscle toxicity with statins.
Pharmacoepidemiology and drug safety 2010;19(3):223-31.
2009: Mao Mao; Alice Matimba; Maria Gabriella Scordo; Arzu Gunes; Hakan Zengil; Norio Yasui-Furukori; Collen M Masimirembwa; Marja-Liisa Dahl
Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis.
Pharmacogenomics 2009;10(9):1447-55.
2009: Arzu Gunes; Gul Ozbey; Elif Hilal Vural; Canan Uluoglu; Maria Gabriella Scordo; Hakan Zengil; Marja-Liisa Dahl
Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Pharmacogenomics 2009;10(5):769-78.
2009: M Samuelsson; Marja-Liisa Dahl; R C Gupta; Conny Nordin
Taurine in plasma and CSF: a study in healthy male volunteers.
Amino acids 2009;36(3):529-33.
2009: Arzu Gunes; Kristina I Melkersson; Maria Gabriella Scordo; Marja-Liisa Dahl
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.
Journal of clinical psychopharmacology 2009;29(1):65-8.
2008: Arzu Gunes; Edoardo Spina; Marja-Liisa Dahl; Maria Gabriella Scordo
ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Therapeutic drug monitoring 2008;30(5):628-33.
2008: M O Magnusson; Marja-Liisa Dahl; Jonas Cederberg; Mats O Karlsson; Rikard Sandström
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin.
Clinical pharmacology and therapeutics 2008;84(1):52-62.
2008: Arzu Gunes; Marja-Liisa Dahl
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.
Pharmacogenomics 2008;9(5):625-37.
2008: Arzu Gunes; Marja-Liisa Dahl; Edoardo Spina; Maria Gabriella Scordo
Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.
European journal of clinical pharmacology 2008;64(5):477-82.
2008: Jonatan D Lindh; Lennart Holm; Marja-Liisa Dahl; Lars Alfredsson; Anders Rane
Incidence and predictors of severe bleeding during warfarin treatment.
Journal of thrombosis and thrombolysis 2008;25(2):151-9.
2007: Georgios Panagiotidis; Holger W Arthur; Jonatan D Lindh; Marja-Liisa Dahl; Folke Sjöqvist
Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Therapeutic drug monitoring 2007;29(4):417-22.
2007: Kristina Melkersson; Maria Gabriella Scordo; Arzu Gunes; Marja-Liisa Dahl
Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients.
The Journal of clinical psychiatry 2007;68(5):697-704.
2007: A-K Hamberg; Marja-Liisa Dahl; M Barban; Maria Gabriella Scordo; Mia Wadelius; Vittorio Pengo; Roberto Padrini; E Niclas Jonsson
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.
Clinical pharmacology and therapeutics 2007;81(4):529-38.
2007: Arzu Gunes; Maria Gabriella Scordo; Peeter Jaanson; Marja-Liisa Dahl
Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Psychopharmacology 2007;190(4):479-84.
2006: Vural Ozdemir; Arzu Gunes; Marja-Liisa Dahl; Maria Gabriella Scordo; Bryn Williams-Jones; Toshiyuki Someya
Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?
Pharmacogenomics 2006;7(8):1199-210.
2006: Federica Varsaldi; Gianluca Miglio; Maria Gabriella Scordo; Marja-Liisa Dahl; Laura Maria Villa; Aldo Biolcati; Grazia Lombardi
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.
European journal of clinical pharmacology 2006;62(9):721-6.
2006: Karin Hedenmalm; Cüneyt Güzey; Marja-Liisa Dahl; Qun-Ying Yue; Olav Spigset
Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
Journal of clinical psychopharmacology 2006;26(2):192-7.
2006: Jan Wålinder; Jiri Prochazka; Anders Odén; Ingemar Sjödin; Marja-Liisa Dahl; Johan Ahlner; Finn Bengtsson
Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Human psychopharmacology 2006;21(3):151-8.
2006: Maria Gabriella Scordo; Marja-Liisa Dahl; Edoardo Spina; Francesco Cordici; Maria Grazia Arena
No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population.
Pharmacological research : the official journal of the Italian Pharmacological Society 2006;53(2):162-5.
2006: Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Clinical pharmacology and therapeutics 2006;79(1):103-13.
2005: Maria Gabriella Scordo; Edoardo Spina; Marja-Liisa Dahl; Giuliana Gatti; Emilio Perucca
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Basic & clinical pharmacology & toxicology 2005;97(5):296-301.
2004: Kristina Melkersson; Marja-Liisa Dahl; Anna-Lena Hulting
Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism.
Psychopharmacology 2004;175(1):1-6.
2004: Melih O Babaoglu; Umit Yasar; Mia Sandberg; Erik Eliasson; Marja-Liisa Dahl; S Oguz Kayaalp; Atila Bozkurt
CYP2C9 genetic variants and losartan oxidation in a Turkish population.
European journal of clinical pharmacology 2004;60(5):337-42.
2004: Per Holmgren; Björn Carlsson; Anna-Lena Zackrisson; Bertil Lindblom; Marja-Liisa Dahl; Maria Gabriella Scordo; Henrik Druid; Johan Ahlner
Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19.
Journal of analytical toxicology 2004;28(2):94-104.
2004: Ann Josefsson; Gunilla Sydsjö; Göran Berg; Marja-Liisa Dahl; Mia Wadelius; Conny Nordin
CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum.
Nordic journal of psychiatry 2004;58(1):61-4.
2003: Kristina Melkersson; Marja-Liisa Dahl
Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.
Psychopharmacology 2003;170(2):157-66.
2003: Jonatan D Lindh; Anita Annas; Lennart Meurling; Marja-Liisa Dahl; Ayman Al-Shurbaji
Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
European journal of clinical pharmacology 2003;59(5-6):401-6.
2003: Pedro Dorado; Roland Berecz; Maria-Jesús Norberto; Umit Yasar; Marja-Liisa Dahl; Adrián LLerena
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.
European journal of clinical pharmacology 2003;59(3):221-5.
2003: Per Dalén; Marja-Liisa Dahl; Hyung-Keun Roh; Gunnel Tybring; M Eichelbaum; G R Wilkinson; Leif Bertilsson
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
British journal of clinical pharmacology 2003;55(6):630-4.
2003: Laimonas Griskevicius; Umit Yasar; Mia Sandberg; Mats Hidestrand; Erik Eliasson; Gunnel Tybring; Moustapha Hassan; Marja-Liisa Dahl
Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.
European journal of clinical pharmacology 2003;59(2):103-9.
2003: Roland Berecz; Alfredo de la Rubia; Pedro Dorado; Pedro M Fernández-Salguero; Marja-Liisa Dahl; Adrián LLerena
Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
European journal of clinical pharmacology 2003;59(1):45-50.
2002: Maria Gabriella Scordo; Vittorio Pengo; Edoardo Spina; Marja-Liisa Dahl; Milena Gusella; Roberto Padrini
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
Clinical pharmacology and therapeutics 2002;72(6):702-10.
2002: Umit Yasar; Marja-Liisa Dahl; Magnus Christensen; Erik Eliasson
Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.
British journal of clinical pharmacology 2002;54(2):183-5.
2002: Margareta Reis; Gunilla Olsson; Björn Carlsson; Jöns Lundmark; Marja-Liisa Dahl; Jan Wålinder; Johan Ahlner; Finn Bengtsson
Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting.
Journal of clinical psychopharmacology 2002;22(4):406-13.
2002: Elisabeth Skogh; Margareta Reis; Marja-Liisa Dahl; Jöns Lundmark; Finn Bengtsson
Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
Therapeutic drug monitoring 2002;24(4):518-26.
2002: Peeter Jaanson; Toomas Marandi; Raul-Allan Kiivet; Veiko Vasar; Siiri Vään; Jan-Olof Svensson; Marja-Liisa Dahl
Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Psychopharmacology 2002;162(1):67-73.
2002: Umit Yasar; Erik Eliasson; Marja-Liisa Dahl
Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
Carcinogenesis 2002;23(4):665; author reply 667-8.
2002: Magnus Christensen; Gunnel Tybring; Kazuo Mihara; Norio Yasui-Furokori; Juan Antonio Carrillo; Sara Isabel Ramos; Katarina Andersson; Marja-Liisa Dahl; Leif Bertilsson
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Clinical pharmacology and therapeutics 2002;71(3):141-52.
2002: Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.
British journal of clinical pharmacology 2002;53(2):111-22.
2002: Marja-Liisa Dahl
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Clinical pharmacokinetics 2002;41(7):453-70.
2002: Niklas Finnstrom; B Ask; Marja-Liisa Dahl; M Gadd; Anders Rane
Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes.
The pharmacogenomics journal 2002;2(2):111-6.
2002: Umit Yasar; Cecilia Forslund-Bergengren; Gunnel Tybring; Pedro Dorado; Adrián LLerena; Folke Sjöqvist; Erik Eliasson; Marja-Liisa Dahl
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Clinical pharmacology and therapeutics 2002;71(1):89-98.
2001: Umit Yasar; Erik Eliasson; C Forslund-Bergengren; Gunnel Tybring; M Gadd; Folke Sjöqvist; Marja-Liisa Dahl
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
European journal of clinical pharmacology 2001;57(10):729-35.
2001: Björn Carlsson; G Olsson; Margareta Reis; J Walinder; Conny Nordin; Jöns Lundmark; Maria Gabriella Scordo; Marja-Liisa Dahl; Finn Bengtsson; Johan Ahlner
Enantioselective analysis of citalopram and metabolites in adolescents.
Therapeutic drug monitoring 2001;23(6):658-64.
2001: Maria Gabriella Scordo; Eleni Aklillu; Umit Yasar; Marja-Liisa Dahl; Edoardo Spina; Magnus Ingelman-Sundberg
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
British journal of clinical pharmacology 2001;52(4):447-50.
2001: Hyung-Keun Roh; J Y Chung; D Y Oh; C S Park; Jan-Olof Svensson; Marja-Liisa Dahl; Leif Bertilsson
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
British journal of clinical pharmacology 2001;52(3):265-71.
2001: Julia Kirchheiner; Kim Brøsen; Marja-Liisa Dahl; LF Gram; S Kasper; Ivar Roots; Folke Sjöqvist; Edoardo Spina; Jürgen Brockmöller
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.
Acta psychiatrica Scandinavica 2001;104(3):173-92.
2001: Gunnel Tybring; Mats Hidestrand; Mikael Oscarson; Magnus Ingelman-Sundberg; Marja-Liisa Dahl; Erik Eliasson
Role of CYP2C9 polymorphism in losartan oxidation.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(7):1051-6.
2001: G Alvan; Leif Bertilsson; Marja-Liisa Dahl; Magnus Ingelman-Sundberg; Folke Sjöqvist
Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 2):580-5.
2001: E E Kvist; Ayman Al-Shurbaji; Marja-Liisa Dahl; C Nordin; Gunnar Alván; L Ståhle
Quantitative pharmacogenetics of nortriptyline: a novel approach.
Clinical pharmacokinetics 2001;40(11):869-77.
2000: Maria Gabriella Scordo; Edoardo Spina; P Romeo; Marja-Liisa Dahl; Leif Bertilsson; Inger Johansson; Folke Sjöqvist
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
European journal of clinical pharmacology 2000;56(9-10):679-83.
2000: Juan Antonio Carrillo; Magnus Christensen; Sara Isabel Ramos; C Alm; Marja-Liisa Dahl; Julio Benitez; Leif Bertilsson
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Therapeutic drug monitoring 2000;22(4):409-17.
2000: Marja-Liisa Dahl; Folke Sjöqvist
Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.
Therapeutic drug monitoring 2000;22(1):114-7.
1999: Maria Gabriella Scordo; Edoardo Spina; Graziella Facciolà; Angela Avenoso; I Johansson; Marja-Liisa Dahl
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Psychopharmacology 1999;147(3):300-5.
1999: Agneta Wennerholm; Inger Johansson; Amosy Massele; M Lande; C Alm; Y Aden Abdi; Marja-Liisa Dahl; Magnus Ingelman-Sundberg; Leif Bertilsson; Lars ´Gustafsson
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
Pharmacogenetics 1999;9(6):707-14.
1999: Per Dalén; Marja-Liisa Dahl; M Eichelbaum; Leif Bertilsson; G R Wilkinson
Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
Pharmacogenetics 1999;9(6):697-706.
1999: Maria Luisa Bernal; Blanca Sinues; Inger Johansson; Roman A McLellan; Agneta Wennerholm; Marja-Liisa Dahl; Magnus Ingelman-Sundberg; Leif Bertilsson
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.
Pharmacogenetics 1999;9(5):657-60.
1999: Umit Yasar; Erik Eliasson; Marja-Liisa Dahl; I Johansson; Magnus Ingelman-Sundberg; Folke Sjöqvist
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Biochemical and biophysical research communications 1999;254(3):628-31.
1998: Mikael Oscarson; H Gullstén; Arja Rautio; M L Bernal; Blanca Sinues; Marja-Liisa Dahl; J H Stengård; Olavi Pelkonen; Hannu Raunio; Magnus Ingelman-Sundberg
Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase.
FEBS letters 1998;438(3):201-5.
1998: B Eiermann; Per-Olof Edlund; Agneta Tjernberg; Per Dalén; Marja-Liisa Dahl; Leif Bertilsson
1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(11):1096-101.
1998: Mohamed Sager; Rein Seensalu; Gunnel Tybring; Marja-Liisa Dahl; Leif Bertilsson
CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Scandinavian journal of gastroenterology 1998;33(10):1034-8.
1998: Karin Herrlin; Amosy Massele; Mary Jande; C Alm; Gunnel Tybring; Y A Abdi; Agneta Wennerholm; Inger Johansson; Marja-Liisa Dahl; Leif Bertilsson; Lars ´Gustafsson
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Clinical pharmacology and therapeutics 1998;64(4):391-401.
1998: Q Y Yue; Z H Zhong; Gunnel Tybring; Per Dalén; Marja-Liisa Dahl; Leif Bertilsson; Folke Sjöqvist
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
Clinical pharmacology and therapeutics 1998;64(4):384-90.
1998: H Yamada; Marja-Liisa Dahl; Matti Viitanen; Bengt Winblad; Folke Sjöqvist; Lars Lannfelt
No association between familial Alzheimer disease and cytochrome P450 polymorphisms.
Alzheimer disease and associated disorders 1998;12(3):204-7.
1998: H Yamada; Marja-Liisa Dahl; Lars Lannfelt; Matti Viitanen; Bengt Winblad; Folke Sjöqvist
CYP2D6 and CYP2C19 genotypes in an elderly Swedish population.
European journal of clinical pharmacology 1998;54(6):479-81.
1998: Per Dalén; Marja-Liisa Dahl; M L Bernal Ruiz; J Nordin; Leif Bertilsson
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.
Clinical pharmacology and therapeutics 1998;63(4):444-52.
1998: Raul-Allan Kiivet; Marja-Liisa Dahl; Adrián LLerena; M Maimets; Björn Wettermark; Roland Berecz
Antibiotic use in 3 European university hospitals.
Scandinavian journal of infectious diseases 1998;30(3):277-80.
1998: Erik G Jönsson; Marja-Liisa Dahl; Hyung-Keun Roh; M Jerling; Göran C Sedvall
Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia.
Psychiatric genetics 1998;8(1):25-8.
1997: Kazuo Mihara; Koichi Otani; Gunnel Tybring; Marja-Liisa Dahl; L Bertilsson; Sunao Kaneko
The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients.
Journal of clinical psychopharmacology 1997;17(6):467-71.
1997: Olav Spigset; Karin Hedenmalm; Marja-Liisa Dahl; Bengt-Erik Wiholm; Rune Dahlqvist
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Acta psychiatrica Scandinavica 1997;96(5):379-84.
1997: Per Dalén; C Frengell; Marja-Liisa Dahl; Folke Sjöqvist
Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.
Therapeutic drug monitoring 1997;19(5):543-4.
1997: Toomas Marandi; Marja-Liisa Dahl; L Rägo; Raul-Allan Kiivet; Folke Sjöqvist
Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
European journal of clinical pharmacology 1997;53(3-4):257-60.
1997: Leif Bertilsson; Marja-Liisa Dahl; Gunnel Tybring
Pharmacogenetics of antidepressants: clinical aspects.
Acta psychiatrica Scandinavica. Supplementum 1997;391():14-21.
1996: Hyung-Keun Roh; Marja-Liisa Dahl; Gunnel Tybring; H Yamada; Young-Nam Cha; Leif Bertilsson
CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
Pharmacogenetics 1996;6(6):547-51.
1996: Hyung-Keun Roh; Marja-Liisa Dahl; Inger Johansson; Magnus Ingelman-Sundberg; Young-Nam Cha; Leif Bertilsson
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Pharmacogenetics 1996;6(5):441-7.
1996: Inger Johansson; E Lundqvist; Marja-Liisa Dahl; Magnus Ingelman-Sundberg
PCR-based genotyping for duplicated and deleted CYP2D6 genes.
Pharmacogenetics 1996;6(4):351-5.
1996: Juan Antonio Carrillo; Marja-Liisa Dahl; Jan-Olof Svensson; C Alm; I Rodríguez; Leif Bertilsson
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
Clinical pharmacology and therapeutics 1996;60(2):183-90.
1996: T Marandi; Marja-Liisa Dahl; Raul-Allan Kiivet; L Rägo; Folke Sjöqvist
Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Pharmacology & toxicology 1996;78(5):303-7.
1996: Collen M Masimirembwa; Lars ´Gustafsson; Marja-Liisa Dahl; Y A Abdi; Julia A Hasler
Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.
British journal of clinical pharmacology 1996;41(4):344-6.
1996: M Jerling; Marja-Liisa Dahl; Anna Aberg-Wistedt; B Liljenberg; N E Landell; Leif Bertilsson; Folke Sjöqvist
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.
Clinical pharmacology and therapeutics 1996;59(4):423-8.
1996: Marja-Liisa Dahl; Leif Bertilsson; C Nordin
Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.
Psychopharmacology 1996;123(4):315-9.
1995: M Chang; Marja-Liisa Dahl; Gunnel Tybring; E Götharson; Leif Bertilsson
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Pharmacogenetics 1995;5(6):358-63.
1995: Raul-Allan Kiivet; Adrián LLerena; Marja-Liisa Dahl; L Rootslane; J Sánchez Vega; T Eklundh; Folke Sjöqvist
Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.
British journal of clinical pharmacology 1995;40(5):467-76.
1995: Marja-Liisa Dahl; Inger Johansson; Leif Bertilsson; Magnus Ingelman-Sundberg; Folke Sjöqvist
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
The Journal of pharmacology and experimental therapeutics 1995;274(1):516-20.
1995: Marja-Liisa Dahl; QY Yue; Hyung-Keun Roh; Inger Johansson; Juliette Säwe; Folke Sjöqvist; Leif Bertilsson
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
Pharmacogenetics 1995;5(3):159-64.
1995: M Chang; Gunnel Tybring; Marja-Liisa Dahl; E Götharson; Mohamed Sager; Rein Seensalu; Leif Bertilsson
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.
British journal of clinical pharmacology 1995;39(5):511-8.
1994: Leif Bertilsson; Juan Antonio Carrillo; Marja-Liisa Dahl; Adrián LLerena; C Alm; U Bondesson; Leif H Lindström; I Rodriguez de la Rubia; S Ramos; Julio Benitez
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
British journal of clinical pharmacology 1994;38(5):471-3.
1994: Marja-Liisa Dahl; Gunnel Tybring; C E Elwin; C Alm; K Andreasson; M Gyllenpalm; Leif Bertilsson
Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.
Clinical pharmacology and therapeutics 1994;56(2):176-83.
1994: Marja-Liisa Dahl; Adrián LLerena; U Bondesson; Leif H Lindström; Leif Bertilsson
Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
British journal of clinical pharmacology 1994;37(1):71-4.
1993: Inger Johansson; E Lundqvist; L Bertilsson; Marja-Liisa Dahl; F Sjöqvist; Magnus Ingelman-Sundberg
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(24):11825-9.
1993: Adrián LLerena; A G Herraíz; J Cobaleda; Inger Johansson; Marja-Liisa Dahl
Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
Clinical pharmacology and therapeutics 1993;54(6):606-11.
1993: Leif Bertilsson; C O Meese; QY Yue; Marja-Liisa Dahl; Magnus Ingelman-Sundberg; Inger Johansson; Juliette Säwe; M Eichelbaum
Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Pharmacogenetics 1993;3(2):94-100.
1993: Marja-Liisa Dahl; Leif Bertilsson
Genetically variable metabolism of antidepressants and neuroleptic drugs in man.
Pharmacogenetics 1993;3(2):61-70.
1993: L Bertilsson; Marja-Liisa Dahl; F Sjöqvist; A Aberg-Wistedt; Mats Humble; Inger Johansson; E Lundqvist; Magnus Ingelman-Sundberg
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.
Lancet 1993;341(8836):63.
1993: Marja-Liisa Dahl; L Iselius; C Alm; Jan-Olof Svensson; D Lee; Inger Johansson; Magnus Ingelman-Sundberg; Folke Sjöqvist
Polymorphic 2-hydroxylation of desipramine. A population and family study.
European journal of clinical pharmacology 1993;44(5):445-50.
1993: Leif Bertilsson; Marja-Liisa Dahl; B Ekqvist; Adrián LLerena
Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation.
Psychopharmacology series 1993;10():230-7.
1992: Adrián LLerena; Marja-Liisa Dahl; B Ekqvist; Leif Bertilsson
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
Therapeutic drug monitoring 1992;14(3):261-4.
1992: Adrián LLerena; C Alm; Marja-Liisa Dahl; B Ekqvist; Leif Bertilsson
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
Therapeutic drug monitoring 1992;14(2):92-7.
1992: Adrián LLerena; Marja-Liisa Dahl; B Ekqvist; Leif Bertilsson
Genetic factors in the metabolism of haloperidol.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():84A-85A.
1992: Gilles Paintaud; Gunnar Alván; Marja-Liisa Dahl; A Grahnén; J Sjövall; Jan-Olof Svensson
Nonlinearity of amoxicillin absorption kinetics in human.
European journal of clinical pharmacology 1992;43(3):283-8.
1992: Marja-Liisa Dahl; I Johansson; Q Y Yue; Juliette Säwe; Leif Bertilsson; M Ingelman-Sundberg; F Sjöqvist
Interethnic differences in drug oxidation. Implications for the utilization of antidepressants and neuroleptics.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():88A-89A.
1992: Marja-Liisa Dahl; Inger Johansson; M P Palmertz; Magnus Ingelman-Sundberg; Folke Sjöqvist
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
Clinical pharmacology and therapeutics 1992;51(1):12-7.
1991: Marja-Liisa Dahl; B Ekqvist; J Widén; Leif Bertilsson
Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans.
Acta psychiatrica Scandinavica 1991;84(1):99-102.
1991: Marja-Liisa Dahl; Conny Nordin; Leif Bertilsson
Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline.
Therapeutic drug monitoring 1991;13(3):189-94.
1991: Leif Bertilsson; K Otani; Marja-Liisa Dahl; Conny Nordin; Anna Aberg-Wistedt
Stereoselective efflux of (E)-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patients.
Pharmacology & toxicology 1991;68(2):100-3.
1991: Conny Nordin; Leif Bertilsson; Marja-Liisa Dahl; B Resul; G Toresson; Folke Sjöqvist
Treatment of depression with E-10-hydroxynortriptyline--a pilot study on biochemical effects and pharmacokinetics.
Psychopharmacology 1991;103(3):287-90.